Brii Biosciences Limited, yon konpayi milti-nasyonal k ap devlope terapi inovatè pou maladi ki gen bezwen medikal enpòtan ki pa satisfè ak gwo fado sante piblik, jodi a te anonse ke Administrasyon Nasyonal Pwodwi Medikal (NMPA) nan Lachin te akòde apwobasyon nan antikò netralize monoklonal konpayi an (mAb) terapi, konbinezon amubarvimab/romlusevimab (anvan konbinazon BRII-196/BRII-198), pou tretman pou granmoun ak pasyan pedyatrik (laj 12-17 ki peze omwen 40 kg) ak kalite COVID-19 modere ak nòmal ki gen gwo risk. pou pwogresyon nan maladi grav, ki gen ladan entène lopital oswa lanmò. Endikasyon pasyan pedyatrik (laj 12-17 ki peze omwen 40 kg) se anba yon apwobasyon kondisyonèl.
eTurboNews atik yo se pou abonnés sèlman. Abònman se GRATIS.
Abonnés konekte isit la Klike la a pou w abònman GRATIS
Abonnés konekte isit la Klike la a pou w abònman GRATIS
KISA POU RETIRE NAN ATIK SA A:
- Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the National Medical Products Administration (NMPA) of China has granted approval of the company’s monoclonal neutralizing antibody (mAb) therapy, the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination), for the treatment in adults and pediatric patients (age 12-17 weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death.
- The indication of pediatric patients (age 12-17 weighing at least 40 kg) is under a conditional approval.
- Abònman se GRATIS.
